DRG Market Assessment 보고서
질환 개요 및 예측, 역학 인텔리전스, 바이오시밀러 인텔리전스, China In-depth 등 폭넓은 시장 인텔리전스를 확인해 보세요.
Prostate Cancer (First-Line [Chemotherapy-Naive] Metastatic Castrate-Resistant) | DecisionBase | US | 2015
What Advantages Do Surveyed Oncologists and Payers Believe Emerging Therapies Must Offer to Gain Traction in This Increasingly Competitive Market? In recent years, several new, high-priced…
Systemic Lupus Eryhtematosus (What Market Access Levers and Barriers Will Emerging Biologics for SLE Face in Europe?) | Physician & Payer Forum | EU5 | 2014
In 2011, GlaxoSmithKline’s Benlysta became the first biological treatment ever approved for systemic lupus erythematosus (SLE) and the first drug approved for SLE in more than 50 years. However,…
EU5 Market Access Opportunities and Challenges for Current and Emerging Rheumatoid Arthritis Agents Amid the Launches of Oral Jak Inhibitors and Biosimilars | Physician & Payer Forum | EU5 | 2014
Rheumatoid arthritis (RA) is a complex autoimmune condition characterized by chronic and progressive joint inflammation that typically results in permanent, debilitating tissue damage. Biological…